Dr. Lal PathLabs Limited (DLPL), one of India’s most trusted diagnostic chains, has significantly enhanced its genomics capabilities by integrating Illumina’s cutting-edge NovaSeq™ X Series into its dedicated genomics division, Genevolve. This advancement positions DLPL to deliver faster, more accurate, and large-scale genomic insights.
Next-Gen Sequencing Reaches New Heights
As per Illumina’s press release, the NovaSeq™ X Series, equipped with Illumina’s revolutionary XLEAP-SBS™ chemistry, sets new benchmarks in throughput, accuracy, and sustainability. The NovaSeq X Plus can sequence over 20,000 whole genomes annually, more than double the capacity of its predecessor. With this unmatched performance, DLPL is now able to push the boundaries of genetic research and unlock insights that were previously out of reach.
Leadership Comments on Strategic Upgrade
Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs Limited, emphasized the impact of the investment:
“With the addition of Illumina’s NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence. This upgrade broadens our capabilities and reinforces our contribution to India’s dynamic genomics ecosystem.”
Genevolve Strengthens Its Pioneering Role
Since its launch in 2019, Genevolve has rapidly established itself as a DNA-based center of excellence. The integration of Illumina’s latest technology further cements its position as a leader in next-generation sequencing (NGS). By combining NGS and AI, DLPL now offers faster, more sensitive, and actionable insights that support better health outcomes.
Dr. Vandana Lal, Executive Director at DLPL, shared:
“At Genevolve, our mission has always been to push the boundaries of genomic innovation. Adding the NovaSeq X Series affirms our commitment to precision and speed, bringing transformative insights to patients and researchers alike.”
Illumina Commends India’s Genomic Momentum
Mr. Gregory Essert, General Manager for Emerging Markets at Illumina, acknowledged DLPL’s role in accelerating genomic access in India:
“NovaSeq X Series reflects Illumina’s leadership in sequencing technology. We’re proud to see it adopted by institutions like Dr. Lal PathLabs that are leading scientific discovery and expanding access to genomics in India.”
Partnership Aims to Accelerate Innovation
Mr. Praveen Gupta, Managing Director of Premas Life Sciences, highlighted the broader vision:
“Our goal has always been to accelerate India’s adoption of next-generation sequencing. Supporting DLPL’s integration of the NovaSeq X platform is a key milestone in driving transformative research and innovation.”
Engaging India’s Scientific Community
Together, Dr. Lal PathLabs and Illumina plan to work closely with India’s medical and research communities. Their joint aim is to build awareness, expand capacity, and encourage genomics-based decision-making—paving the way for a future of personalized and precision medicine in India.